Diab SG, Elledge RM, Clark GM. - Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst, 2000, 92, 550-556. (Pubitemid 30212316)
Yancik R, Wesley MN, Ries LA, et al. - Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 2001, 285, 885-892. (Pubitemid 32171549)
Extermann M, Aapro M, Bernabei R, et al. - Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol, 2005, 55, 241-252. (Pubitemid 41219694)
Bouchardy C, Rapiti E, Blagojevic S, et al. - Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol, 2007, 25, 1858-1869. (Pubitemid 46854419)
Fisher B, Anderson S, Bryant J, et al. - Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 2002, 347, 1233-1241. (Pubitemid 35176242)
Kataja V, Castiglione M. - Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009, 20, 10-14.
Abrial C, Durando X, Mouret-Reynier MA, et al. - Role of neo-adjuvant hormonal therapy in the treatment of breast cancer : a review of clinical trials. Int J Gen Med, 2009, 2, 129-140.
Hughes KS, Schnaper LA, Berry D, et al. - Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med, 2004, 351, 971-977. (Pubitemid 39166260)
Clarke M, Collins R, Darby S, et al. - Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival : an overview of the randomised trials. Lancet, 2005, 366, 2087-2106. (Pubitemid 39166260)
Beadle BM, Woodward WA, Buchholz TA. - The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol, 2011, 21, 26-34.
Antonini N, Jones H, Horiot JC, et al. - Effect of age and radiation dose on local control after breast conserving treatment : EORTC trial 22881-10882. Radiother Oncol, 2007, 82, 265-271. (Pubitemid 46341468)
Early Breast Cancer Trialists' Collaborative Groupe (EBCTCG). - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials. Lancet, 2005, 365, 1687-1717.
Crivellari D, Sun Z, Coates AS, et al. - Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer : the BIG 1-98 trial. J Clin Oncol, 2008, 26, 1972-1979.
Sideras K, Ingle JN, Ames MM, et al. - Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol, 2010, 28, 2768-2776.
Eidtmann H, de Boer R, Bundred N, et al. - Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : 36-month results of the ZO-FAST Study. Ann Oncol, 2010, 21, 2188-2194.
Goldhirsch A, Ingle JN, Gelber RD, et al. - Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 2009, 20, 1319-1329.
Muss HB, Woolf S, Berry D, et al. - Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA, 2005, 293, 1073-1081. (Pubitemid 40300281)
Extermann M, Bonetti M, Sledge GW, et al. - MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer, 2004, 40, 1193-1198. (Pubitemid 38526338)
Kornblith AB, Lan L, Archer L, et al. - Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol, 2011, 29, 1022-1028.
Jones S, Holmes FA, O'Shaughnessy J, et al. - Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide : 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol, 2009, 27, 1177-1183.
Chirivella I, Bermejo B, Insa A, et al. - Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat, 2009, 114, 479-484.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005, 353, 1659-1672. (Pubitemid 41464705)
Sawaki M, Tokudome N, Mizuno T, et al. - Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients : randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol, 2011, 41, 709-712.
Wilcken N, Hornbuckle J, Ghersi D. - Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev, 2003, CD002747.
Carrick S, Parker S, Wilcken N, et al. - Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2005, CD003372.
Harris L, Batist G, Belt R, et al. - Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 2002, 94, 25-36. (Pubitemid 34049039)
Ghersi D, Wilcken N, Simes RJ. - A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer, 2005, 93, 293-301. (Pubitemid 43080031)
Kaufman B, Mackey JR, Clemens MR, et al. - Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer : results from the randomized phase III TAnDEM study. J Clin Oncol, 2009, 27, 5529-5537.
Raff JP, Rajdev L, Malik U, et al. - Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer, 2004, 4, 420-427. (Pubitemid 38443465)
Capri G, Chang J, Chen SC, et al. - An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol, 2010, 21, 474-480.
Johnston S, Pippen J, Pivot X, et al. - Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2009, 27, 5538-5546.
Miller K, Wang M, Gralow J, et al. - Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 2007, 357, 2666-2676.
Aapro MS, Link H. - September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist, 2008, 13, 33-36.
Hedenus M, Birgegard G. - The role of iron supplementation during epoietin treatment for cancer-related anemia. Med Oncol, 2009, 26, 105-115.
Aapro MS, Bohlius J, Cameron DA, et al. - 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer, 2011, 47, 8-32.
Stopeck AT, Lipton A, Body JJ, et al. - Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol, 2010, 28, 5132-5139.
